98 related articles for article (PubMed ID: 12222996)
1. Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction.
Piqué JM; Feu F; de Prada G; Röhss K; Hasselgren G
Clin Pharmacokinet; 2002; 41(12):999-1004. PubMed ID: 12222996
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects.
Hassan-Alin M; Andersson T; Niazi M; Röhss K
Eur J Clin Pharmacol; 2005 Jan; 60(11):779-84. PubMed ID: 15578172
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome.
Vinayek R; Amantea MA; Maton PN; Frucht H; Gardner JD; Jensen RT
Gastroenterology; 1991 Jul; 101(1):138-47. PubMed ID: 2044903
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of conivaptan use in patients with severe hepatic impairment.
Marbury T; Fox J; Kaelin B; Pavliv L
Drug Des Devel Ther; 2017; 11():373-382. PubMed ID: 28243060
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole.
Centerholt C; Ekblom M; Odergren T; Borgå O; Popescu G; Molz KH; Couturier A; Weil A
Eur J Clin Pharmacol; 2003 Jun; 59(2):117-22. PubMed ID: 12734608
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis.
Andersson T; Olsson R; Regårdh CG; Skånberg I
Clin Pharmacokinet; 1993 Jan; 24(1):71-8. PubMed ID: 8448974
[TBL] [Abstract][Full Text] [Related]
8. The anti-secretory effect and pharmacokinetics of omeprazole in chronic liver disease.
McKee RF; MacGilchrist AJ; Garden OJ; Forrest JA; Carter DC
Aliment Pharmacol Ther; 1988 Oct; 2(5):429-37. PubMed ID: 2979265
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.
Tran A; Rey E; Pons G; Pariente-Khayat A; D'Athis P; Sallerin V; Dupont C
Clin Pharmacol Ther; 2002 May; 71(5):359-67. PubMed ID: 12011821
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects.
Hassan-Alin M; Andersson T; Bredberg E; Röhss K
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):665-70. PubMed ID: 11214773
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of omeprazole in patients with liver cirrhosis and extrahepatic portal venous obstruction.
Kumar R; Chawla YK; Garg SK; Dixit RK; Satapathy SK; Dhiman RK; Bhargava VK
Methods Find Exp Clin Pharmacol; 2003 Oct; 25(8):625-30. PubMed ID: 14671680
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
[TBL] [Abstract][Full Text] [Related]
14. Variation in omeprazole pharmacokinetics in a random Iranian population: a pilot study.
Noubarani M; Kobarfard F; Motevalian M; Keyhanfar F
Biopharm Drug Dispos; 2012 Sep; 33(6):324-31. PubMed ID: 22890488
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
16. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit.
Lin XB; Huang F; Tong L; Xia YZ; Wu JJ; Li J; Hu XG; Liang T; Liu XM; Zhong GP; Cai CJ; Chen X
Int J Infect Dis; 2020 Apr; 93():345-352. PubMed ID: 32109625
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oral omeprazole in llamas.
Poulsen KP; Smith GW; Davis JL; Papich MG
J Vet Pharmacol Ther; 2005 Dec; 28(6):539-43. PubMed ID: 16343286
[TBL] [Abstract][Full Text] [Related]
19. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients.
Buijk SE; Gyssens IC; Mouton JW; Metselaar HJ; Groenland TH; Verbrugh HA; Bruining HA
J Antimicrob Chemother; 2004 Jul; 54(1):199-205. PubMed ID: 15175266
[TBL] [Abstract][Full Text] [Related]
20. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
